文献速递支持与姑息治疗

HIV感染者的癌症治疗

Treating Cancer in People With HIV.
PubMed 文献 · J Clin Oncol · 2023-06-02

本文为《临床肿瘤学杂志》肿瘤学大查房系列综述,围绕HIV感染者(PWH)的癌症诊疗展开:即使抗逆转录病毒治疗控制良好,PWH某些癌症的终生风险仍升高,且癌症相关生存低于一般人群。文中讨论了机会性感染、药物相互作用、多原发癌等管理挑战,并指出PWH一般应接受与一般人群相同的标准全剂量抗癌治疗,除非有特定方案的数据。

要点

  • PWH即使HIV控制良好,某些癌症终生风险仍升高,癌症相关生存低于一般人群。
  • PWH一般应接受与一般人群相同的标准全剂量抗癌治疗,除非有特定癌种方案的数据。
  • 抗PD-(L)-1药物已获FDA批准用于多种HIV相关癌症,但注册试验均排除PWH;多项前瞻性研究及一项国际回顾性研究显示其在PWH中安全有效。

核心结论

  • PWH一般应接受与一般人群相同的标准全剂量抗癌治疗,除非有特定癌种方案的数据;抗PD-(L)-1药物在PWH中安全有效,支持其用于FDA批准的适应证。
  • 未来癌症临床试验应纳入并积极招募PWH,使其平等、及时获得新兴癌症治疗。

研究设计与样本

  • 肿瘤学大查房系列综述:以病例展示引入,随后描述诊断与管理挑战、复习相关文献并总结作者建议的管理方法。
  • 综述范围涵盖HIV相关癌症的诊疗挑战、抗PD-(L)-1药物在PWH中的研究证据及临床试验纳入问题。

主要发现

  • PWH即使HIV经抗逆转录病毒治疗控制良好,某些癌症的终生风险仍升高。
  • 尽管过去数十年HIV与癌症诊疗取得巨大进步,PWH的癌症相关生存仍低于一般人群。
  • 许多因素可能导致PWH接受不恰当的剂量调整、被排除在新兴治疗与临床试验之外,或完全未接受抗癌治疗。
  • 多项前瞻性研究和一项针对晚期癌症PWH的国际回顾性研究显示,抗PD-(L)-1药物在预期癌种和CD4+ T细胞计数范围内安全有效。

关键数值与推荐

  • PWH一般应接受与一般人群相同的标准全剂量抗癌治疗,除非有特定癌种方案在PWH中的数据。
  • 靶向PD-1和PD-L1的药物已获美国食品药品监督管理局(FDA)批准用于多种HIV相关癌症,包括霍奇金淋巴瘤、宫颈癌、头颈癌、肝细胞癌和非小细胞肺癌。
  • PWH被排除在所有支持上述药物FDA批准的临床试验之外。
  • 支持抗PD-(L)-1药物用于PWH的证据来自多项前瞻性研究和一项晚期癌症PWH的国际回顾性研究,显示其在预期癌种和CD4+ T细胞计数范围内安全有效。

临床怎么用

  • 治疗HIV相关癌症需要多学科团队,处理合并的机会性感染、潜在的药物相互作用以及同一患者同时存在一种以上癌症的情况。
  • PWH一般应接受与一般人群相同的标准全剂量抗癌治疗,除非有特定癌种方案在PWH中的数据。
  • 抗PD-(L)-1药物可用于PWH的FDA批准适应证,依据为多项前瞻性研究和一项国际回顾性研究显示其安全有效。
  • 未来癌症临床试验应纳入并积极招募PWH,使其平等、及时获得新兴癌症治疗。

局限性

  • PWH被排除在所有支持PD-1和PD-L1药物FDA批准的临床试验之外。
  • 许多因素可能导致PWH接受不恰当的剂量调整、被排除在新兴治疗与临床试验之外,或完全未接受抗癌治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.People with HIV (PWH) have an increased lifetime risk of developing certain cancers, even when HIV is well-controlled with antiretroviral therapy. Despite the tremendous advancements in HIV and cancer care over the past several decades, PWH have lower cancer-related survival compared with the general population. Treating HIV-associated cancers requires a multidisciplinary team to manage concurrent opportunistic infections, potential drug-drug interactions, and the co-occurrence of more than one cancer in the same patient. Many factors may lead PWH to receive inappropriate dose adjustments, exclusion from emerging therapies and clinical trials, or no cancer therapy at all. In general, PWH should receive the same standard, full-dose cancer therapy used in the general population unless there are data for specific cancer regimens in PWH. Agents targeting PD-1 and PD-L1 have US Food and Drug Administration (FDA)-approved indications in many HIV-associated cancers, including Hodgkin lymphoma, cervical cancer, head and neck cancer, hepatocellular carcinoma, and non-small-cell lung cancer; however, PWH were excluded from all clinical trials that led to FDA approval of these agents. Several prospective studies and an international retrospective study of PWH with advanced cancer have shown anti-PD-(L)-1 agents to be safe and effective across expected cancer types and CD4+ T-cell counts, supporting their use in PWH for FDA-approved indications. Learning from the experience in anti-PD-(L)-1 agents, future cancer clinical trials should include and seek to actively enroll PWH, so that they have equal and timely access to emerging cancer therapies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lurain K. Treating Cancer in People With HIV. J Clin Oncol. 2023. PMID: 37267514. doi:10.1200/JCO.23.00737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。